Reviewer's report

**Title:** Single Arm NCRI Feasibility Study of CHOP in Combination with Ofatumumab in Induction and Maintenance for Patients with Newly Diagnosed Richter's Syndrome

**Version:** 1  **Date:** 23 August 2014

**Reviewer:** Preetesh N Jain

**Reviewer's report:**

Discretionary Revisions

1. It will be interesting if the authors also include some histopathologic criteria to confirm DLBCL type of Richter's versus other types of transformation such as "accelerated CLL" or Histiocytic sarcoma transformation.

Major Compulsory Revisions

1. No figures or tables were included in the manuscript.
2. None of the results were provided
3. Explain whether a combination of O-hyperCVAD could be better than O-CHOP?
4. Whether the dose of ofatumumab chosen is based on pharmacokinetics? 1000 or 2000 mg/m2.
5. Authors should discuss data from R-CHOP in Richter's and compare with O-CHOP.
7. Explain whether the pts who achieve CR will be considered for SCT after maint or before maint.? Whether the characteristics of prior CLL determine their treatment decision?
8. Clonality with prior CLL - will it affect the treatment decision?
**Level of interest:** An article of outstanding merit and interest in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**
None